Table 5.
Resistance mutations | Drugs | Reference | Detected resistance mutations | Detected resistance mutations |
---|---|---|---|---|
Case number | n = 82 | N = 60 | ||
C316Y/N/H | Dasabuvir, tegobuvir, HCV796 | [13–16, 34] | — | C316N 100% (60/60) |
S365T/A | Tegobuvir, HCV796 | [15, 16] | S365F 1.2% (1/82) S365P 1.2% (1/82) |
S365A 3.33% (2/60) |
S368T | Dasabuvir | [14] | S368A 1.2% (1/82) S368L 1.2% (1/82) |
— |
Case number | n = 4 | n = 51 | ||
M414T/I/V/L | Dasabuvir, tegobuvir, HCV796 | [13, 15, 16] | M414Q 50% (2/4) | M414L 5.88% (3/51) |
L419M/V | Tegobuvir, HCV796 | [15, 16] | L419I 100% (4/4) | — |
M423T/I/V | Tegobuvir, HCV796 | [15, 16] | — | M423I 1.96% (1/51) |
Y448C/H | Dasabuvir, tegobuvir | [13–16] | — | Y448H 1.96% (1/51) |
I482L/V/T | Tegobuvir | [15, 16] | I482L 100% (4/4) | I482T 5.88% (3/51) I482V 1.96% (1/51) |
V494S/Q/L/A/T | Tegobuvir | [15, 16] | V494A 50% (2/4) V494C 25% (1/4) |
V494L 3.92% (2/51) |
P495S/Q/L/A/T | Tegobuvir | [15, 16] | — | P495S 5.88% (3/51) |
P496A/S | Tegobuvir | [15, 16] | — | P496T 5.88% (3/51) |
V499A | JTK-109, deleobuvir | [15] | V499A 100% (4/4) | V499A 15.69% (8/51) V499T 1.96% (1/51) V499I 3.92% (2/51) |